ebitda

Morgan Stanley maintained an equal-weight rating on Dr Reddy’s Labs, citing missed Q4FY26 estimates and a slight delay in Semaglutide ramp-up. Kotak Institutional Equities recommended buying Dixon Technologies, driven by strong consumer electronics performance. Citigroup reiterated its buy on Max Financial, highlighting margin improvements and sustained growth. Macquarie rated Berger Paints underperform, despite a constructive outlook.

Analysts are bullish on Adani Ports, Indus Tower, and Voda Idea, citing strong performance and growth prospects. Kotak Bank shows solid operating metrics, though RoE lags peers. Bharti Airtel's outlook remains positive despite potential tariff hike delays, with industry repair seen as intact.

Indian Hotels saw strong Q4FY26 results with revenue up 14% and profit by 15%, driven by robust hotel operations. UPL's Q4FY26 revenue grew 18%, but earnings were impacted by provisions. Oberoi Realty's Mumbai market shows promise, while PVR reported a 24% revenue jump. Nuvama's wealth and asset servicing segments are performing well.

Stock market recommendations: Granules, and UltraTech Cement have been picked as the top stock recommendations from the week starting May 4, 2026 by Motilal Oswal Wealth Management Research Desk. Let’s take a look:

Kotak Securities maintains an add rating on PNB with a revised target of Rs 125, citing steady profitability despite weaker core earnings than peers. Jefferies reiterates a buy on Marico, raising its target to Rs 960, with management confident in strong ebitda growth.

Analysts are bullish on Bajaj Finance, IIFL Finance, and Navin Fluorine, citing strong quarterly results and positive future outlooks. Federal Bank is seen as fairly valued, while Waaree Engineering's revenue beat expectations despite margin concerns. Investors are watching these key companies closely.

Cellecor reported a robust financial year ending March 31, 2026, with net revenues soaring to Rs 1,292 crores, a 26% increase. Net profit after tax also saw a significant 28% jump. This impressive growth was fueled by product expansion, a wider retail footprint including partnerships with major chains, and increased adoption in smaller markets, alongside strong online sales.

Saudi Arabia’s decision to end funding for LIV Golf after 2026 has sparked wider scrutiny of its global sports spending. However, TKO Group executives insist Saudi backing for UFC, WWE and boxing remains secure, with planned events in the Middle East continuing. The move reflects a possible strategic shift within the Public Investment Fund amid rising costs and changing priorities.

India's largest pharma company, Sun Pharma, has made its biggest overseas acquisition, buying Organon & Co for $11.8 billion. This deal significantly expands Sun Pharma's global presence and product range. It will double the company's revenue and ebitda. The acquisition positions Sun Pharma as a major player in women's health and biosimilars. This strategic move strengthens Sun Pharma's position in the global pharmaceutical market.

Middle East conflicts are driving crude oil prices above $100 per barrel, significantly boosting earnings for Indian upstream oil giants like ONGC and Oil India. While these companies anticipate substantial profit increases due to higher realisations, they face challenges from declining production in aging fields.

O2C Division Hit Hard By Rising Costs, Supply Chain Disruptions

Stock market recommendations: For the trading week starting April 27, 2026, Tata Steel, and Cyient DLM are the top stock picks from Motilal Oswal Wealth Management Research Desk.

Sun Pharmaceutical Industries Ltd has agreed to acquire US-based Organon & Co for $11.75 billion in an all-cash deal. This significant outbound acquisition is expected to close in early 2027, strengthening Sun Pharma's global presence in women's health and biosimilars.

Goldman Sachs maintained a buy rating on Reliance Industries, citing potential margin recovery and strong retail growth despite a Q4FY26 ebitda miss. Nomura also holds a buy on Axis Bank, highlighting attractive valuations and strong loan growth. HSBC recommends buying Shriram Finance, anticipating RoA expansion despite revised AUM growth forecasts.

Indian pharmaceutical giant Sun Pharma is set to acquire US-based Organon & Co. for $11.75 billion in an all-cash deal. This landmark acquisition, one of India's largest overseas ventures, will propel Sun Pharma into the top 25 global pharma companies. The move significantly bolsters its presence in women's health and biosimilars, expanding its global reach across 150 countries.

Infosys faces investor pressure, with its market value dropping significantly despite strong March quarter results. A subdued FY27 revenue growth forecast and industry-wide shifts towards cost efficiency and AI-driven productivity are impacting its outlook. While AI presents new opportunities, it also pressures core business margins.

Reliance Industries' Q4 FY26 net profit declined 12.5% year-on-year to Rs 16,971 crore, impacted by the Middle East crisis affecting its oil and chemicals business. Despite this, revenue rose 13% to Rs 2.98 lakh crore, with strong contributions from digital services and retail. Jio Platforms reported a 13% profit increase to Rs 7,935 crore.